deucravacitinib
bms
['deucra']
 rct available today in a&amp;r and discussed later today at #acr22: efficacy and safety of deucravacitinib, an oral, selective, allosteric tyk2 inhibitor, in patients with active sle article: session 11/13 at 12:45pm: 
The official social media feed of Arthritis & Rheumatology, Arthritis Care & Research, and ACR Open Rheumatology.